Phase 2 N=38 Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)
Prostate Cancer
Primary: Two Year Progression-free Survival — 64.9 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=22 The Use of Oracea and Epiduo Forte in Severe Acne Patients
Acne
Primary: Investigator Global Assessment (IGA) Score — 0; 0; 20; 0 Participants
Phase 4 N=36 A Clinical Trial to Prevent New Onset Diabetes After Transplantation
Prevention of New Onset Diabetes Among Kidney Transplant Patients
Primary: The Incidence of New Onset of Diabetes After Transplant (NODAT) 12 Months After Kidney Transplantation — 3; 1 Participants — p=0.87
N/A N=53 Integrated Treatment for Smoking Cessation & Anxiety in People With HIV
Nicotine Dependence · Symptoms of Anxiety · HIV
Primary: Treatment Acceptability — 17 Participants
Phase 4 N=13 Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish
Onychomycosis of Toenail
Primary: Percentage of Nail Polish Disruption Using the Likert Scale — 0.6; 0 percentage of nail polish disruption
Phase 2 N=50 Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 28 weeks
Phase 2 N=10 A Study of RPL554 in Patients With Cystic Fibrosis
Cystic Fibrosis
Primary: AUC by Dose — 7699; 2342 pg*h/mL
Phase 1 N=6 Absorption & Elimination of Radiolabelled GSK2269557
Pulmonary Disease, Chronic Obstructive
Primary: Area Under Concentration-time Curve (AUC) From Time 0 (Pre-dose) to Infinite Time (0 to Inf) and AUC From Time 0 (Pre-dose) to Last Time of Quantifiable Concentration (0…
Phase 3 N=292 Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis
Ulcerative Colitis
Primary: Percentage of Participants With a Clinical Response at Week 10 in Induction Phase — 32.9; 39.6 percentage of participants — p=0.2722
Phase 2 N=77 MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: MK-0646 Maximum Tolerable Dose — 0; 0; 0; 2 participants
Phase 4 N=4,389 Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen
COPD
Primary: Trough FEV1 at Week 12 for Group: Glycopyrronium vs. Short-acting Bronchodilators (SABA and/or SAMA as Monotherapy or in Free or FDC) — 1.8264; 1.8916 Liters — p=0.0180
Phase 4 N=552 Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest Congestion
Healthy Subjects
Primary: Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s) — 29; 0; 29; 29 Number of Events
Phase 3 N=130 Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection
Hepatitis C Virus Infection
Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 93.0 percentage of participants — p=0.009
N/A N=71 Treatment Response of Geriatric Depression
Depression
Primary: Montgomery Asberg Depression Rating Scale (Depression Severity) — 12.23 units on a scale
N/A N=2 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
Glioblastoma
Primary: Binding of 89Zr-J591